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The aim of the present study was to examine if obese individuals with obesity-related
somatic comorbidity (i.e., hypertension, diabetes, sleep apnea, dyslipidemia, pain disor-
der) perform worse in neurocognitive tasks compared to obese individuals without any
somatic disorder. Neurocognitive functioning was measured by a computerized test bat-
tery that consisted of the following tasks: Corsi BlockTappingTest, Auditory Word Learning
Task,Trail MakingTest-Part B, StroopTest, LabyrinthTest, and a four-disk version of theTower
of Hanoi. The total sample consisted of 146 patients, the majority (N =113) suffered from
obesity grade 3, 26 individuals had obesity grade 2, and only 7 individuals obesity grade
1. Ninety-eight participants (67.1%) reported at least one somatic disorder (Soma+-group).
Hypertension was present in 75 individuals (51.4%), type 2 diabetes in 34 participants
(23.3%), 38 individuals had sleep apnea (26.0%), 16 suffered from dyslipidemia (11.0%), and
14 individuals reported having a chronic pain disorder (9.6%). Participants without a coexist-
ing somatic disorder were younger [MSoma =33.7, SD=9.8 vs. MSoma =42.7, SD .0,+ =11−
F (1, 144)=23.01, p<0.001] and more often female [89.6 and 62.2%, 2χ (1)=11.751,
p=0.001] but did not differ with respect to education, regular binge eating, or depres-
sive symptoms from those in the Soma+-group. The Soma−-group performed better on
cognitive tasks related to memory and mental flexibility. However, the group differences
disappeared completely after controlling for age. The findings indicate that in some obese
patients increasing age may not only be accompanied by an increase of obesity severity
and by more obesity-related somatic disorders but also by poorer cognitive functioning.
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INTRODUCTION
Research indicates an association between obesity and neurocog-
nitive dysfunction (1–4). The causal pathways for this relationship,
however, remain poorly understood. One potential explanation
concerns the association between obesity and comorbid med-
ical conditions that in turn may lead to cognitive impairment.
It remains uncertain whether the proposed cognitive decline can
be attributed to effects of a specific obesity-related somatic disor-
der or rather to additive effects of multiple conditions. Cognitive
dysfunction seen in patients with obesity might be caused by the
presence of several somatic disorders that are prevalent in obese
individuals such as diabetes type 2, hypertension, sleep apnea,
dyslipidemia, or chronic pain.
Type 2 diabetes that is characterized by reduced insulin sen-
sitivity and relative insulin deficiency is related to microvascu-
lar and macrovascular complications that may affect the brain
(5–7). The underlying mechanisms of diabetes-related cognitive
impairment, however, are difficult to establish due to the pres-
ence of several confounding somatic comorbidities. There exists
evidence that cerebrovascular disease contributes substantially
to decreased cognitive abilities in patients with diabetes type 2
(6, 7). Similarly, chronic elevation in blood pressure is com-
mon in obese persons and linked to an increased risk for alter-
ations in the cerebral artery structure, vascular dementia, and
Alzheimer-type neuropathy (8). Hypertension affects cerebral cir-
culation that may adversely influence performance in cognitive
tasks, in particular those assessing executive functions (9–11).
Another vascular risk factor for cognitive dysfunction is dys-
lipidemia that is strongly associated with diabetes type 2 and
hypertension in obese individuals (12, 13). Furthermore, sleep
apnea has been associated with a higher risk for cognitive impair-
ment (14, 15). Sleep fragmentation and cessation or reduction
of breathing during sleep resulting in recurrent hypoxemia can
contribute to structural and functional brain abnormalities that
are related to cognitive dysfunction (16–18). In addition, there
exists evidence for the negative influence of chronic pain on
cognitive performance (19, 20). Possible mechanisms involved
in pain-related cognitive impairment include the overlap in
brain morphology, neurotransmitters, and other neural media-
tors that are involved in both pain processing and cognition,
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altered neuroplasticity, and dysregulated neurochemistry [for
review see (20)].
There are other variables that can affect cognitive functioning.
It is well known that morbidly obese individuals suffer from psy-
chiatric disorders [e.g., (21–23)]. For example, depressive symp-
toms are prevalent in obese persons (24) and may account for
their cognitive abilities (25). One of the most common psychiatric
disorders reported in morbidly obese patients is binge eating dis-
order (BED) with prevalence rates up to 50% (23, 26–29). BED
is characterized by experiencing loss of control while eating an
unusual large amount of food and is therefore linked to food-
related high impulsivity (30). Few studies have examined cognitive
functions, in particular food-unrelated decision-making, in obese
individuals with BED reporting mixed results. While one study
found decision-making deficits in overweight and obese women
with BED compared to those without (31) others did not (32, 33).
The inconsistency between the studies could be caused by differ-
ent cognitive tasks and by sampling characteristics [e.g., different
body mass index (BMI) ranges].
Furthermore, higher education is often related to better per-
formance in cognitive tasks (32, 34). Last but not least, there have
been many reports regarding the inverse association between age
and performance in cognitive tasks. The question at which age the
cognitive decline starts, however, remains unresolved (34, 35).
The aim of the present study was to examine the relationship
between neurocognitive performance and somatic disorders in
obese patients taking into account BMI, depressive and eating
disorder symptoms, and education. Based on the literature, we
expected a reduced neurocognitive performance in obese individ-
uals with any obesity-related somatic disorder compared to those
without.
MATERIALS AND METHODS
PARTICIPANTS AND STUDY DESIGN
Participation in the study was completely voluntarily. Inclusion
criteria were a BMI≥ 30 kg/m2, age between 18 and 65 years, and
sufficient German language skills. Exclusion criteria were any neu-
rological disorder, psychosis, dementia, current substance abuse,
developmental or learning disorders, sensory impairments, and
intellectual disability.
Between January 2011 and May 2012, 84 patients consider-
ing bariatric surgery who were seen for a routine preoperative
psychiatric evaluation at the University Hospital Erlangen or the
Hannover Medical School and 62 subjects from a psychosomatic
inpatient unit in Bad Bramstedt were recruited. The total sample
consisted of 146 patients (71.2% women, 28.8% men) with an
average age of 39.8 years (SD= 11.4, Range 18–65). The major-
ity (N = 113) suffered from obesity grade 3 (BMI≥ 40 kg/m2), 26
individuals had obesity grade 2 (BMI: 35–39.9 kg/m2), and only
7 individuals had obesity grade 1 (BMI: 30–34.9 kg/m2). All par-
ticipants gave written informed consent according to procedures
approved by the Institutional Ethics Committees of the three study
sites.
ASSESSMENTS
The participants provided information on education, height, and
weight. Information on medication and the following somatic
disorders was taken from patients’ charts of the surgical depart-
ments or the inpatient unit: hypertension, diabetes, sleep apnea,
dyslipidemia, and pain disorder.
To measure eating disorder symptoms, the German version of
the Eating Disorder Examination-Questionnaire (EDE-Q) (36)
was used. This questionnaire consists of specific items to assess
objective binge eating episodes (OBE; i.e., eating an objectively
large amount of food with a sense of loss of control). Regular
binge eating was defined as eight or more OBEs during the past
28 days.
The German version of the 9-item Patient Health Question-
naire depression scale (PHQ-9) (37) was administered in order to
assess depressive symptoms. The PHQ-9 scores each of the nine
DSM-IV criteria for depression from 0 (not at all) to 3 (nearly
every day).
Neurocognitive functioning was measured by a computerized
test battery that consisted of the following neurocognitive tasks.
The Corsi Block Tapping Test (CBT) was administered to assess
visual attention and working memory (38). Participants had to
reproduce several sequences of block tappings displayed only once
by the computer. When the sequence was correctly copied, the
number of cubes which had to be touched was increased step-
wise. The outcome variable of this task was the total number of
correct answers.
To assess verbal memory, we administered an auditory verbal
learning task (wordlist) in which a list of 15 not associated words
was presented five times. Participants were asked to reproduce as
many words as possible after each of the five trials. The number of
correctly recalled words per trial was registered and the total of all
correct answers across the five trials was used as outcome variable.
The Trail Making Test-Part B (TMT-B) (39) was used to exam-
ine mental flexibility and the ability to switch attention. Partici-
pants had to tap numbers (1–9) and digits (A–I) in an alternating
sequence as quickly and as accurately as possible within three tri-
als. The mean time to completion per trial (in seconds) was used
as dependent variable in this task.
The Stroop Test is a well known diagnostic tool for assessing
selective attention and response inhibition (40). In this study, the
answers were given not verbally but by pressing the corresponding
button on the touch screen. The number of correctly identi-
fied words in the interference condition was used as dependent
variable.
The Labyrinth Test was used to assess spatial memory, planning,
and error utilization (41). Participants had to find a hidden path
through a spatial maze. The task was completed after the hidden
path was found two times without errors. The total number of
errors during this task was used as dependent variable.
Finally, a four-disk version of the Tower of Hanoi (ToH) was
used to measure planning abilities (42). The ratio between the
number of ideal disk moves and the number of actually needed
disk moves (effectivity) was the dependent variable.
DATA ANALYSIS
Analyses were performed using IBM SPSS Statistics v.20. The total
sample was divided in a group without any somatic disorder and
a group with at least one somatic disorder. Univariate analyses of
variance (ANOVA) and χ2-tests were used to compare the groups
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in terms of sociodemographic variables, BMI and depression, as
appropriate. In a second step, the groups were compared with
regard to their performance in the neurocognitive tasks. These
analyses were controlled for potential confounding variables that
were found to be different between the groups in the afore-
mentioned analyses (ANCOVA). The group comparisons were
then repeated subsequently for specific somatic disorders (i.e.,
hypertension yes/no, diabetes yes/no, sleep apnea yes/no).
To investigate the relationship between the number of somatic
disorders and the performance in neurocognitive tasks, we con-
ducted Pearson correlations. Finally, to examine the association
between neurocognitive performance and the presence of any
somatic disorder we performed a set of logistic regression analyses
adjusting for variables that differed between the two groups (age,
gender, BMI).
The group comparisons regarding cognitive functioning and
the regressions were made on the basis of Bonferroni-corrected
significance levels.
RESULTS
SOMATIC COMORBIDITY, BMI, MEDICATION, SOCIODEMOGRAPHIC
CHARACTERISTIC, EATING DISORDER SYMPTOMS, AND DEPRESSION
Based on patients’ charts, 67.1% of the total sample (N = 98) suf-
fered from at least one somatic disorder (Soma+-group). Hyper-
tension was present in 75 individuals (51.4%), type 2 diabetes in 34
participants (23.3%), 38 individuals had sleep apnea (26.0%), 16
suffered from dyslipidemia (11.0%), and 14 individuals reported
having a chronic pain disorder (9.6%). The mean number of
disorders in the Soma+-group ranged from 1 to 5 (M = 1.81,
SD= 0.94). Almost half of that group reported suffering from
only one somatic disorder (49%), 26.5% had two, and 20.4%
three somatic disorders. The number of somatic disorders in the
Soma+-group was positively related to age (r = 0.293, p< 0.01).
The groups did not differ in terms of any psychopharmaco-
logical treatment including neuroleptics, mood stabilizer, antide-
pressants, anxiolytics, stimulants, or anticonvulsive drugs [Soma−:
37.5% vs. Soma+: 45.4%,χ2(1)= 0.811, p= 0.368]. Many partic-
ipants reported taking antidepressant medication [Soma−: 33.3%
vs. Soma+: 43.3%,χ2(1)= 1.329, p= 0.249]. While only two par-
ticipants in the Soma−-group took non-opiate pain medication,
81.4% of participants with somatic comorbidity had at least one
of the following pharmacological treatments: insulin and/or non-
insulin anti-diabetic medication, antihypertensive agents, opiate
or non-opiate pain medication, or cholesterol lowering drugs.
As shown in Table 1, patients with any somatic disorder were
substantially older and had a significantly higher BMI than those
without somatic disorders. There were more male patients in the
Soma+-group. The groups did not differ significantly from each
other with regard to education.
According to the EDE-Q mean total scores which were avail-
able from 134 patients, we did not find any significant group
differences in terms of eating disorder symptoms including binge
eating. The mean number of OBEs during the past 28 days did
not differ between the two groups [M Soma+= 4.27, SD= 6.34
and M Soma−= 4.78, SD= 7.18, F(1, 133)= 0.175, p= 0.676].
Regular binge eating was found in 21.3% of the Soma+ group
and 28.9% of the Soma− group [χ2(1)= 0.935, p= 0.334].
Table 1 | Comparison of sociodemographic characteristics, BMI, eating
disorder, and depressive symptoms between individuals without any
somatic disorder (Soma−) and those with any somatic disorder
(Soma+).
Soma−
(N=48)
Soma+
(N=98)
Group comparison
M (SD) M (SD) ANOVA
Age (years) 33.7 (9.8) 42.7 (11.0) F (1, 144)=23.008, p<0.001
BMI 43.9 (8.4) 48.4 (8.3) F (1, 144)=9.483, p=0.001
PHQ-9 10.6 (6.6) 9.4 (5.8) F (1, 124)=1.088, p=0.299
EDE-Q 3.13 (1.05) 2.90 (1.00) F (1, 130)=1.538, p=0.217
N (%) N (%) χ2-test
OBESITY GRADE
Grade I 4 (8.3) 3 (3.1) χ2(2)=14.904, p=0.001
Grade II 16 (33.3) 10 (10.2)
Grade III 28 (58.3) 85 (86.7)
Gender, female 43 (89.6) 61 (62.2) χ2(1)=11.751, p=0.001
SCHOOLYEARS
≤9 9 (19.6) 33 (34.4) χ2(3)=4.029, p=0.258
10 23 (50.0) 42 (43.8)
11–13 9 (19.6) 11 (11.5)
>13 5 (10.9) 10 (10.4)
PHQ-9, Patient Health Questionnaire, depression scale (data were available from
43 participants without any somatic disorder and 83 participants with at least one
somatic disorder); EDE-Q, Eating Disorder Examination-Questionnaire (data were
available from 44 participants without any somatic disorder and 88 participants
with at least one somatic disorder).
Information on depressive symptoms was available from 126
patients (86% of the total sample). The PHQ-9 data indi-
cated a lack of significant group differences with respect to
depression.
COMPARISON OF PERFORMANCE IN NEUROCOGNITIVE TASKS
BETWEEN PATIENTS WITHOUT ANDWITH SOMATIC DISORDERS
As can be seen in Table 2, the results of the univariate ANOVA
suggest differences between the Soma− and the Soma+ groups
in three of six tasks, particularly in the CBT, the wordlist, and the
TMT-B. After controlling for gender, only the difference in the CBT
remained significant. After adjusting for age all group differences
disappeared completely (Table 2).
Figures 1–3 present the unadjusted group differences of task
performance in the CBT, the wordlist, and the TMT-B by the
presence/absence of specific disorders, in particular hyperten-
sion, diabetes, and sleep apnea indicating the strongest effect on
cognitive performance for hypertension. Similarly to the afore-
mentioned findings, after controlling for age the differences were
no longer significant (data not reported here but available upon
request).
Due to the relatively low prevalence of dyslipidemia and
pain disorder in the present sample we did not conduct group
comparisons based on the absence or presence of these conditions.
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Table 2 | Comparison of performances in neurocognitive tasks between individuals without any somatic disorder (Soma−, N =48) and those
with any somatic disorder (Soma+, N =98).
Soma− Soma+ Group comparison
M (SD)a M (SD)a ANOVA ANCOVA
controlled
for age
ANCOVA
controlled
for gender
ANCOVA
controlled
for BMI
Corsi Block Tapping Test 7.31 (2.38) 5.64 (2.19) F (1, 144)=17.50** F (1, 143)=6.89 F (1, 142)=10.39* F (1, 143)=16.34**
Wordlist 58.75 (8.23) 52.83 (8.92) F (1, 143)=14.85** F (1, 142)=4.69 F (1, 141)=3.24 F (1, 142)=13.35**
Trail Making Test, Part B 6792.06 (2216.35) 8420.36 (3321.52) F (1, 143)=9.44* F (1, 142)=0.95 F (1, 141)=6.58 F (1, 142)=11.49**
Stroop Test 19.85 (0.36) 19.58 (1.14) F (1, 144)=2.61 F (1, 143)=0.03 F (1, 142)=0.001 F (1, 143)=4.59
Austin Maze 43.00 (35.90) 48.97 (30.50) F (1, 136)=1.04 F (1, 135)=0.79 F (1, 134)=0.08 F (1, 135)=0.72
Tower of Hanoi 0.52 (0.22) 0.51 (0.23) F (1, 143)=0.02 F (1, 142)=0.03 F (1, 141)=0.22 F (1, 142)=0.03
aunadjusted means and standard deviations; *p<0.008 (0.05/6); **p<0.001.
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FIGURE 1 | Number of correct answers in the Corsi BlockTappingTask, unadjusted comparisons.
RELATIONSHIP BETWEEN THE NUMBER OF COMORBID DISORDERS
AND PERFORMANCE IN NEUROCOGNITIVE TASKS
Pearson correlations between the number of somatic disorders and
neurocognitive performance yielded significant negative correla-
tions with regard to the CBT (r =−0.273, p< 0.01), the wordlist
(r =−0.309, p< 0.001), and the TMT-B (r =−0.315, p< 0.001)
but not the other tasks. Since the number of somatic disorders was
positively correlated with age (r = 0.452, p< 0.001), we conducted
additional partial correlations controlling for age. After this, the
correlations mentioned above were no longer significant (CBT:
r =−0.111, ns; wordlist: r =−0.126, ns; TMT-B: r = 0.111, ns).
ASSOCIATION BETWEEN PERFORMANCE IN NEUROCOGNITIVE TASKS
AND SOMATIC COMORBIDITY
Table 3 summarizes the results of hierarchical regression analyses
with the performance in the specific neurocognitive tasks as depen-
dent variables. Age, gender, and BMI were entered into block 1 of
the regressions as control variables. The variable “presence of any
somatic disorder” was entered in a second step. Changes in pre-
dictive ability (R2) were examined to determine significance. As
shown in Table 3, only lower age was associated with more correct
answers in the CBT and with a higher number of correctly recalled
words in the wordlist task. Furthermore, age was positively related
to an increased time to completion in the TMT-B.
DISCUSSION
In the present sample, individuals with any somatic disorder were
about 10 years older and reported significantly higher BMIs than
those without any somatic disorder. Moreover, age was positively
related to the number of obesity-related somatic disorders in the
Soma+-group.
At the first glance, our results concerning cognitive perfor-
mance suggested working and verbal memory deficits (CBT,
wordlist) and poorer mental flexibility (TMT-B) in obese
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FIGURE 2 | Number of correctly recalled words in theWordlistTask, unadjusted comparisons.
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FIGURE 3 | Mean time to completion per trial in theTrail MakingTest-Part B, unadjusted comparisons.
individuals with obesity-related somatic comorbidity. While con-
trolling for BMI did not impact the results substantially, the group
differences disappeared after adjusting for age and gender. Given
the results of the regression analyses with the performance in the
specific neurocognitive tasks as dependent variables and age, gen-
der, BMI, and somatic comorbidity as independent variables, the
better task performance in the Soma−-group seems mainly driven
by younger age. The groups did not differ in terms of education,
depressive symptoms, or eating pathology. Hence, we may assume
that the findings were not confounded by these variables. Taken
together, it appears that worse performance in three of the six
cognitive tasks were rather a problem of older age than of somatic
comorbidity. This is in line with previous research demonstrating
age-related cognitive decline (34, 35).
The findings do not support the assumption that somatic
comorbidity is related to a higher risk for cognitive impairment
in obese individuals. This is surprising given earlier reports on the
association between cognitive dysfunction and somatic comor-
bidity. Though, many of those did not focus on obese individuals
[e.g., (10, 15, 19)]. The discrepancy between our and previous find-
ings reporting cognitive decline in overweight or obese individuals
with somatic comorbidity might be explained by differences in
test selection. Moreover, differences in sampling may account for
the discrepant findings. For example, other studies had included
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Table 3 | Summary of linear regression models concerning the
association between performance in neurocognitive tasks and the
presence of any comorbid somatic disorder, controlled for age,
gender, and BMI.
Corsi Block
TappingTest
Wordlist Trail Making
Test, part B
β R2 β R2 β R2
Step 1
Age −0.39** 0.17** −0.40** 0.22** 0.48** 0.25**
Gender 0.05 0.19* −0.10
BMI −0.07 −0.08 −0.08
Step 2
Age −0.32** 0.20** −0.36** 0.23** 0.45** 0.26**
Gender −0.00 0.16 −0.08
BMI −0.03 −0.05 −0.10
Somatic
comorbidity
−0.23 −0.11 0.08
*p<0.017 (0.05/3); **p< 0.001.
either substantially younger [e.g., (17)] or older [e.g., (9)] indi-
viduals or those with lower BMIs [e.g., (7)]. It is certainly possible
that the lack of group differences in the present investigation was
related to a ceiling effect in both the Soma+ and the Soma− group
given the high BMI range. According to previous reports, obese
individuals suffer from impaired cognitive function compared to
normal-weight controls [e.g., (3, 4, 43, 44)]. However, the present
investigation did not include a normal-weight control group that
is a shortcoming.
On the other hand, our results are consistent with other reports
of lacking differences in cognitive function between individuals
with and without somatic comorbidity. Recently, Singh-Manou
et al. (45) examined the association between midlife obesity,
metabolic abnormalities (i.e., dyslipidemia, hypertension, hyper-
glycemia), and cognitive decline in early old age in a large lon-
gitudinal study (N = 6401). The sample consisted of 582 obese
adults. In this study, the metabolically healthy obese participants
did not have a better cognitive profile than individuals with meta-
bolic abnormalities. Also, no significant differences were found
between the two groups with regard to cognitive decline over a
10 years period.
There are some other limitations that need to be acknowledged.
First, the diagnosis of both depressive symptoms and binge eat-
ing based on questionnaires instead of a standardized interview is
concerning. Second, medication for somatic disorders could have
influenced the task performance. Also, the group with somatic
comorbidity is twice as large as the group without any somatic
disorder that might have biased the results.
In conclusion, our findings indicate that in some obese patients
increasing age may not only be accompanied by an increase of obe-
sity severity and by more obesity-related somatic disorders but also
by poorer cognitive functioning. Further studies should include
control groups matched for age, gender, and education to exam-
ine whether somatic comorbidity may add a negative impact on
cognition above the effect of age.
ACKNOWLEDGMENTS
We kindly thank Dr. Laszlo Gaal (Bernried) for his support dur-
ing the course of the study and the two reviewers for their helpful
comments.
REFERENCES
1. Cournot M, Marquié JC, Ansiaun
D, Martinaud C, Fonds H, Fer-
riere J, et al. Relation between
body mass index and cogni-
tive function in healthy middle-
aged men and women. Neurology
(2006) 67:1208–14. doi:10.1212/01.
wnl.0000238082.13860.50
2. Dahl AK, Hassing LB. Obesity
and cognitive aging. Epidemiol Rev
(2012). doi:10.1093/epirev/mxs002
[Epub ahead of print].
3. Fagundo AB, de laTorre R, Jiménez-
Murcia S, Agüera Z, Granero
R, Tárrega S, et al. Executive
functions profile in extreme
eating/weight conditions: from
anorexia nervosa to obesity.
PLoS ONE (2012) 7:e43382.
doi:10.1371/journal.pone.0043382
4. Gunstad J, Paul RH, Cohen RA, Tate
DF, Gordon E. Obesity is associated
with memory deficits in young and
middle-aged adults. Eat Weight Dis-
ord (2006) 11:15–9.
5. Elias MF, Elias PK, Sullivan LM,
Wolf PA, D’Agostino RB. Obesity,
diabetes and cognitive deficit: the
Framingham heart study. Neurobiol
Aging (2005) 26S:S11–6. doi:10.
1016/j.neurobiolaging.2005.08.019
6. McCrimmon RJ, Ryan CM, Frier
BM. Diabetes and cognitive dys-
function. Lancet (2012) 379:2291–
9. doi:10.1016/S0140-6736(12)
60360-2
7. Pedersen M, Pedersen KK, Bru-
unsgaard H, Krabbe KS, Thom-
sen C, Færch K, et al. Cogni-
tive functions in middle aged indi-
viduals are related to metabolic
disturbances and aerobic capac-
ity: a cross-sectional study. PLoS
ONE (2012) 7:e51132. doi:10.1371/
journal.pone.0051132
8. Elias MF, Goodell AL, Dore
GA. Hypertension and cognitive
functioning. A perspective in
historical context. Hypertension
(2012) 60:260–8. doi:10.1161/
HYPERTENSIONAHA.111.186429
9. Elias MF, Elias PK, Sullivan LM,
Wolf PA, D’Agostino RB. Lower
cognitive function in the pres-
ence of obesity and hyperten-
sion: the Framingham heart study.
Int J Obes Relat Metab Disord
(2003) 27:260–8. doi:10.1038/sj.ijo.
802225
10. Raz N, Rodrigue KM, Acker D.
Hypertension and the brain: vul-
nerability of the prefrontal regions
and executive functions. Behav Neu-
rosci (2003) 117:1169–80. doi:10.
1037/0735-7044.117.6.1169
11. Saxby BK, Harrington F, McKeith
IG, Wesnes K, Ford GA. Effects of
hypertension on attention, mem-
ory, and executive function in
older adults. Health Psychol (2003)
22:587–91. doi:10.1037/0278-6133.
22.6.587
12. Rincon F, Wright CB. Vascular cog-
nitive impairment. Curr Opin Neu-
rol (2013) 26:29–36. doi:10.1097/
WCO.0b013e32835c4f04
13. van den Berg E, Kloppenborg RP,
Kessels RPC, Kappelle LJ, Biessels
GJ. Type 2 diabetes mellitus, hyper-
tension, dyslipidemia and obesity:
a systematic comparison of their
impact on cognition. Biochim Bio-
phys Acta (2009) 1792:470–81. doi:
10.1016/j.bbadis.2008.09.004
14. Adams N, Strauss ME, Schluchter
M, Redline S. Relation of
measures of sleep-disordered
breathing to neuropsychological
functioning. Am J Respir Crit
Care Med (2001) 163:1626–31.
doi:10.1164/ajrccm.163.7.2004014
15. Naëgelé B, Launois SH, Mazza
S, Feuerstein C, Pépin JL, Lévy
P. Which memory processes are
affected in patients with obstruc-
tive sleep apnea? An evaluation of
3 types of memory. Sleep (2006)
29:533–44.
16. Canessa N, Castronovo V, Cappa
S, Aloia M, Marelli S, Falini A, et
al. Obstructive sleep apnea. Brain
structural changes and neuro cogni-
tive function before and after treat-
ment. Am J Respir Crit Care Med
(2011) 183:1419–26. doi:10.1164/
rccm.201005-0693OC
17. Hannon TS, Rofey DL, Ryan
CM, Clapper DA, Chakravorty S,
Arslanian SA. Relationships among
obstructive sleep apnea, anthropo-
metric measures, and neurocog-
nitive functioning in adolescents
with severe obesity. J Pediatr
(2012) 160:732–5. doi:10.1016/j.
jpeds.2011.10.029
Frontiers in Psychiatry | Eating Behavior August 2013 | Volume 4 | Article 84 | 6
Kiunke et al. Neurocognitive performance in obesity
18. Lal C, Strange C, Bachman D. Neu-
rocognitive impairment in obstruc-
tive sleep apnea. Chest (2012)
14:1601–10. doi:10.1378/chest.11-
2214
19. Landrø NI, Fors EA, Våpenstad LL,
Holthe O, Stiles TC, Borchgrevink
PC. The extent of neurocognitive
dysfunction in a multidisciplinary
pain centre population. Is there
a relation between reported and
tested neuropsychological function-
ing? Pain (2013) 154:972–7. doi:10.
1016/j.pain.2013.01.013
20. Moriarty O, McGuire BE, Finn DP.
The effect of pain on cognitive
function: a review of clinical and
preclinical research. Prog Neurobiol
(2011) 93:385–404. doi:10.1016/j.
pneurobio.2011.01.002
21. Herpertz S, Burgmer R, Stang A,
de Zwaan M, Wolf AM, Chen-
Stute A, et al. Prevalence of men-
tal disorders in normal-weight and
obese individuals with and with-
out weight loss treatment in a Ger-
man urban population. J Psychosom
Res (2006) 61:95–103. doi:10.1016/
j.jpsychores.2005.10.003
22. Kalarchian MA, Marcus MD, Levine
MD, Courcoulas AP, Pilkonis PA,
Ringham RM, et al. Psychiatric dis-
orders among bariatric surgery can-
didates: relationship to obesity and
functional health status. Am J Psy-
chiatry (2007) 164:328–34. doi:10.
1176/appi.ajp.164.2.328
23. Mühlhans B, Horbach T, de Zwaan
M. Psychiatric disorders in bariatric
surgery candidates: a review of the
literature and results of a German
prebariatric surgery sample. Gen
Hosp Psychiatry (2009) 31:414–21.
doi:10.1016/j.genhosppsych.2009.
05.004
24. de Zwaan M, Enderle J, Wagner
S, Mühlhans B, Ditzen B, Gefeller
O, et al. Anxiety and depression
in bariatric surgery patients: a
prospective, follow-up study using
structured clinical interviews. J
Affect Disord (2011) 133:61–8. doi:
10.1016/j.jad.2011.03.025
25. Cserjési R, Luminet O, Poncelet AS,
Lénárd L. Altered executive function
in obesity. Exploration of the role
of affective states on cognitive
abilities. Appetite (2009) 52:
535–9. doi:10.1016/j.appet.2009.01.
003
26. Alger-Mayer S, Rosati C, Polimeni
JM, Malone M. Preoperative binge
eating status and gastric bypass
surgery: a long-term outcome
study. Obes Surg (2009) 19:139–45.
doi:10.1007/s11695-008-9540-9
27. Burgmer R, Grigutsch K, Zipfel
S, Wolf AM, de Zwaan M, Huse-
mann B, et al. The influence of
eating behavior and eating pathol-
ogy on weight loss after gas-
tric restriction operations. Obes
Surg (2005) 15:684–91. doi:10.
1381/0960892053923798
28. Hsu LK, Mulliken B, McDonagh B,
Krupa Das S, Rand W, Fairburn
CG, et al. Binge eating disorder in
extreme obesity. Int J Obes Relat
Metab Disord (2002) 26:1398–403.
doi:10.1038/sj.ijo.0802081
29. Jones-Corneille LR, Wadden TA,
Sarwer DB, Faulconbridge LF, Fab-
ricatore AN, Stack RM. Axis I psy-
chopathology in bariatric surgery
candidates with and without binge
eating disorder: results of struc-
tured clinical interviews. Obes
Surg (2012) 22:389–97. doi:10.
1007/s11695-010-0322-9
30. Schag K, Schönleber J, Teufel M,
Zipfel S, Giel K. Food-related
impulsivity in obesity and binge eat-
ing disorder – a systematic review.
Obes Rev (2013) 14:477–95. doi:10.
1111/obr.12017
31. Svaldi J, Brand M, Tuschen-Caffier
B. Decision-making impairments in
women with binge eating disorder.
Appetite (2010) 54:84–92. doi:10.
1016/j.appet.2009.09.010
32. Davis C, Patte K, Curtis C,
Reid C. Immediate pleasure and
future consequences. A neuropsy-
chological study of binge eating
and obesity. Appetite (2010) 54:
208–13. doi:10.1016/j.appet.2009.
11.002
33. Danner UN, Ouwehand C, van
Haastert NL, Hornsveld H, de Rid-
der DT. Decision making impair-
ments in women with binge eating
disorder in comparison with obese
and normal weight women. Eur Eat
Disord Rev (2012) 20:e56–62. doi:
10.1002/erv.1098
34. Elias MF, Elias PK, D’Agostino
RB, Silbershatz H, Wolf PA. Role
of age, education, and gender
on cognitive performance in
the Framingham Heart Study:
community-based norms. Exp
Aging Res (1997) 23:201–35.
doi:10.1080/03610739708254281
35. Salthouse TA. When does age-
related cognitive decline begin?
Neurobiol Aging (2009) 30:525–7.
doi:10.1016/j.neurobiolaging.2008.
11.012
36. Hilbert A, Tuschen-Caffier B.
Eating Disorder Examination-
Questionnaire. Deutsche Über-
setzung. Münster: Verlag für
Psychotherapie (2006).
37. Löwe B, Spitzer RL, Zipfel S, Herzog
W. PHQ-D: Gesundheitsfragebogen
für Patienten: Manual – Kom-
plettversion und Kurzform, from
Pfizer. (2012). Available from: http:
//infektionskrankheiten.klinikum.
uni-heidelberg.de/fileadmin/
Psychosomatische_Klinik/
download/PHQ_Manual1.pdf
38. Kessels RPC, van Zandvoort
MJE, Postma A, Kappelle LJ,
de Haan EHF. The corsi block-
tapping task: standardization
and normative data. Appl
Neuropsychol (2000) 7:252–8.
doi:10.1207/S15324826AN0704_8
39. Reitan RM. Trail Making Test: Man-
ual for Administration and Scoring.
Tucson, AZ: Reitan Neuropsychol-
ogy Laboratory (1992).
40. Golden CJ. The Stroop Color and
Word Test. Chicago, IL: Stoelting
Company (1978).
41. Bowden SC, Smith LC. What does
the Austin maze measure? Aust Psy-
chol (1994) 29:34–7. doi:10.1080/
00050069408257317
42. Welsh MC, Huizinga M. Tower of
Hanoi disk transfer task: influences
of strategy knowledge and learning
on performance. Learn Individ Dif-
fer (2005) 15:283–98. doi:10.1016/j.
lindif.2005.05.002
43. Galioto R, Spitznagel MB, Strain
G, Devlin M, Cohen R, Paul R, et
al. Cognitive function in morbidly
obese individuals with and without
binge eating disorder. Compr Psychi-
atry (2012) 53:490–5. doi:10.1016/j.
comppsych.2011.09.002
44. Gunstad J, Paul RH, Cohen RA, Tate
DF, Spitznagel MB, Gordon E. Ele-
vated body mass index is associated
with executive dysfunction in other-
wise healthy adults. Compr Psychia-
try (2007) 48:57–61. doi:10.1016/j.
comppsych.2006.05.001
45. Singh-Manou A, Czernichow S,
Elbaz A, Dugravot A, Sabia S,
Hagger-Johnson G, et al. Obe-
sity phenotypes in midlife and
cognition in early old age: the
Whitehall II cohort study. Neurol-
ogy (2012) 79:755–62. doi:10.1212/
WNL.0b013e3182661f63
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 27 May 2013; accepted: 26 July
2013; published online: 13 August 2013.
Citation: Kiunke W, Brandl C, Geor-
giadou E, Gruner-Labitzke K, Horbach
T, Köhler H, de Zwaan M and Müller
A (2013) Performance in neurocogni-
tive tasks in obese patients. Does somatic
comorbidity matter? Front. Psychiatry
4:84. doi: 10.3389/fpsyt.2013.00084
This article was submitted to Frontiers in
Eating Behavior, a specialty of Frontiers
in Psychiatry.
Copyright © 2013 Kiunke, Brandl, Geor-
giadou, Gruner-Labitzke, Horbach, Köh-
ler , de Zwaan and Müller . This is
an open-access article distributed under
the terms of the Creative Commons
Attribution License (CC BY). The use,
distribution or reproduction in other
forums is permitted, provided the orig-
inal author(s) or licensor are cred-
ited and that the original publication
in this journal is cited, in accordance
with accepted academic practice. No use,
distribution or reproduction is permit-
ted which does not comply with these
terms.
www.frontiersin.org August 2013 | Volume 4 | Article 84 | 7
